Empower Cells, Change Lives

Efficacy of Engineered T Cells can be Uncoupled from Toxicities Observed with CAR T Cell Therapy AUSTIN, TX, and HAMILTON, ON, August 3, 2018 – Triumvira Immunologics, Inc., (Triumvira) a privately-held biopharmaceutical company focused on designing safe and more...

Innovative immuno-therapy company welcomes former President and COO of Celgene AUSTIN, Texas & TORONTO--(BUSINESS WIRE)--Triumvira Immunologics, Inc., a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack cancers,...

Brings 30-years of Experience to Company’s Technology Development and Manufacturing Operations AUSTIN, Texas--(BUSINESS WIRE)--Triumvira Immunologics, a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack cancers,...